
BEIJING: The Chinese drugmaker Sinopharm says a subsidiary has received approval for clinical trials of a new vaccine specifically to target the Omicron coronavirus variant.
Two vaccine candidates developed by units of China National Biotec Group (CNBG) have been approved for clinical trials as boosters in Hong Kong, the Sinopharm subsidiary said on Saturday.